Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?

Clinical Endocrinology

Volumn 74, Issue 5, 2011, Pages 547-550

  Compston, Juliet ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE ATROPHY; BONE DENSITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; FRACTURE; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BONE DENSITY CONSERVATION AGENTS; DISEASE MANAGEMENT; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS;

EID: 79953752791     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.03994.x     Document Type: Review

References (30)

1. Compston, J.E., (2010) Management of glucocorticoid-induced osteoporosis. Nature Reviews in Rheumatology, 6, 82-88.
2. Curtis, J.R., Westfall, A.O., Allison, J.J., et al. (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheumatism, 52, 2485-2494. (Pubitemid 41117436)
3. Feldstein, A.C., Elmer, P.J., Nichols, G.A., et al. (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International, 16, 2168-2174. (Pubitemid 41790940)
4. van Staa, T.P., Leufkens, H.G., &, Cooper, C., (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International, 13, 777-787. (Pubitemid 36336722)
5. Compston, J.E., (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Current Rheumatology Reports, 9, 78-84. (Pubitemid 46806312)
6. Kanis, J.A., Johansson, H., Oden, A., et al. (2004) A meta-analysis of prior corticosteroid use and fracture risk. Journal of Bone and Mineral Research, 19, 893-899. (Pubitemid 41103445)
7. Luengo, M., Picado, C., Del Rio, L., et al. (1990) Treatment of steroid-induced osteopenia with calcitonin in corticosteroid dependent asthma. A one-year follow-up study. American Reviews of Respiratory Disease, 142, 104-107. (Pubitemid 20224586)
8. van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al. (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford), 39, 1383-1389. (Pubitemid 32045866)
9. Ip, M., Lam, K., Yam, L., et al. (1994) Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest, 105, 1722-1727. (Pubitemid 24180658)
10. Toogood, J.H., Baskerville, J.C., Markov, A.E., et al. (1995) Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. Journal of Allergy and Clinical Immunology, 96, 157-166.
11. Wong, C.A., Walsh, L.J., Smith, C.J., et al. (2000) Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet, 355, 1399-1403. (Pubitemid 30215962)
12. van Staa, T.P., Leufkens, H.G., &, Cooper, C., (2001) Use of inhaled corticosteroids and risk of fractures. Journal of Bone and Mineral Research, 16, 581-588. (Pubitemid 32173374)
13. van Staa, T.P., Laan, R.F., Barton, I.P., et al. (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis & Rheumatism, 48, 3224-3229. (Pubitemid 37409336)
14. Kanis, J.A., (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359, 1929-1936. (Pubitemid 34615775)
15. University of Sheffield. FRAXA WHO Fracture Risk Assessment Tool [online]. Available from:.
16. Grossman, J.M., Gordon, R., Ranganath, V.K., et al. (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Research, 62, 1515-1526 Available from:.
17. Guidelines working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. 2002 Glucocorticoid- induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London.
18. Homik, J., Cranney, A., Shea, B., et al. (1999) Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001347.doi:. CD001347.
19. Adachi, J.D., Bensen, W.G., Brown, J., et al. (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New England Journal of Medicine, 337, 382-387. (Pubitemid 27328368)
20. Saag, K.G., Emkey, R., Schnitzer, T.J., et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. New England Journal of Medicine, 339, 292-299. (Pubitemid 28366417)
21. Adachi, J.D., Saag, K.G., Delmas, P.D., et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis & Rheumatism, 44, 202-211. (Pubitemid 32113136)
22. Stoch, S.A., Saag, K.G., Greenwald, M., et al. (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. Journal of Rheumatology, 36, 1705-1714.
23. Cohen, S., Levy, R.M., Keller, M., et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a 12 month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & Rheumatism, 42, 2309-2318. (Pubitemid 30333410)
24. Reid, D.M., Hughes, R.A., Laan, R.F., et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Journal of Bone and Mineral Research, 15, 1006-1013. (Pubitemid 30350063)
25. Wallach, S., Cohen, S., Reid, D.M., et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcified Tissue International, 67, 277-285.
26. Reid, D.M., Adami, S., Devogelaer, J.P., et al. (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcified Tissue International, 69, 242-247. (Pubitemid 33035397)
27. Reid, D.M., Devogelaer, J.P., Saag, K., et al. (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373, 1253-1263.
28. Abrahamsen, B., (2010) Adverse effects of bisphosphonates. Calcified Tissue International, 86, 421-435.
29. Saag, K.G., Shane, E., Boonen, S., et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. New England Journal of Medicine, 357, 2028-2039. (Pubitemid 350106710)
30. Saag, K.G., Zanchetta, J.R., Devogelaer, J.P., et al. (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism, 60, 3346-3355.